SLCO2A1 gene is the causal gene for both primary hypertrophic osteoarthropathy and hereditary chronic enteropathy

Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature

(2019) Qiang Wang et al.   Orphanet Journal of Rare Diseases

Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn’s disease

(2018) Junji Umeno et al.   JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial

(2018) Lu Yuan et al.   Journal of Orthopaedic Translation

Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug–Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial

(2016) Ema Washio et al.   Clinical Gastroenterology and Hepatology

A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter

(2015) Junji Umeno et al.   PLoS Genetics

Primary hypertrophic osteoarthropathy: an update

(2013) Zeng Zhang et al.   Frontiers of Medicine

Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis

(2012) Christine P. Diggle et al.   HUMAN MUTATION